TNF Pharmaceuticals (NASDAQ:TNFA) Shares Down 1.3% – Here’s What Happened

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA)’s share price traded down 1.3% on Friday . The company traded as low as $3.75 and last traded at $3.92. 237,138 shares changed hands during trading, a decline of 93% from the average session volume of 3,511,287 shares. The stock had previously closed at $3.97.

TNF Pharmaceuticals Stock Down 1.3%

The stock has a market capitalization of $7.24 million, a PE ratio of -0.02 and a beta of 2.04. The stock has a fifty day moving average of $4.65 and a 200-day moving average of $5.18.

TNF Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.